Q1 Earnings Estimate for Vaxcyte Issued By Leerink Partnrs

Vaxcyte, Inc. (NASDAQ:PCVX) – Investment analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Vaxcyte in a research note issued on Tuesday, February 25th. Leerink Partnrs analyst D. Risinger forecasts that the company will post earnings per share of ($1.01) for the quarter. The consensus estimate for Vaxcyte’s current full-year earnings is ($4.21) per share. Leerink Partnrs also issued estimates for Vaxcyte’s Q2 2025 earnings at ($1.15) EPS, Q3 2025 earnings at ($1.21) EPS, Q4 2025 earnings at ($1.39) EPS, FY2025 earnings at ($4.77) EPS, FY2026 earnings at ($5.46) EPS, FY2027 earnings at ($5.84) EPS, FY2028 earnings at ($5.17) EPS and FY2029 earnings at $1.63 EPS.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.14.

Other equities research analysts also recently issued reports about the stock. The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $140.00 price target on shares of Vaxcyte in a research note on Wednesday. Guggenheim reaffirmed a “buy” rating and issued a $160.00 price target on shares of Vaxcyte in a research note on Wednesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $147.50.

Vaxcyte Trading Down 1.6 %

PCVX opened at $73.02 on Friday. Vaxcyte has a 1-year low of $58.10 and a 1-year high of $121.06. The company has a market cap of $9.10 billion, a P/E ratio of -15.87 and a beta of 0.98. The company has a fifty day moving average price of $84.59 and a two-hundred day moving average price of $94.71.

Insider Activity

In related news, CEO Grant Pickering sold 15,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $92.45, for a total transaction of $1,386,750.00. Following the transaction, the chief executive officer now directly owns 450,301 shares in the company, valued at approximately $41,630,327.45. The trade was a 3.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Teri Loxam sold 6,250 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total transaction of $531,937.50. Following the transaction, the director now owns 7,175 shares in the company, valued at approximately $610,664.25. This trade represents a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 76,616 shares of company stock worth $6,766,481 over the last three months. 3.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Vaxcyte during the fourth quarter worth about $8,487,000. Forum Financial Management LP purchased a new position in Vaxcyte during the fourth quarter worth about $255,000. GF Fund Management CO. LTD. purchased a new position in Vaxcyte during the fourth quarter worth about $214,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Vaxcyte by 15.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 472,964 shares of the company’s stock valued at $38,717,000 after acquiring an additional 64,690 shares during the last quarter. Finally, Windsor Advisory Group LLC grew its position in shares of Vaxcyte by 72.5% during the 4th quarter. Windsor Advisory Group LLC now owns 39,223 shares of the company’s stock valued at $3,211,000 after acquiring an additional 16,479 shares during the period. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.